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See Article, pages 315–321Treatment of hepatorenal syndrome (HRS) with terlipressin and
albumin has become a major breakthrough in the ﬁeld of cirrho-
sis [1]. The introduction of terlipressin as the ﬁrst effective drug
for type-1 HRS represents an advance of comparable importance
to those such as spironolactone for the management of ascites,
propranolol for prevention of variceal bleeding, or norﬂoxacin
for the prevention of spontaneous bacterial peritonitis [2–4].
Over the last decade, since the studies on terlipressin for type-
1 HRS became ﬁrst available, we have learnt that terlipressin in
association with albumin is effective in reversing type-1 HRS,
deﬁned as a reduction of serum creatinine from pretreatment val-
ues to ﬁnal values below 1.5 mg/dl (133 lmol/L), in nearly half of
the patients and that recurrence of HRS after the treatment with-
drawal is uncommon [1,5,6]. We have also learnt that reversal of
type-1 HRS, due to terlipressin and albumin is associated with
improved prognosis, yet this has been proven only in meta-anal-
yses and not in most of the individual randomized studies,
because of the limited number of patients included [7,8]. Finally,
the treatment with terlipressin and albumin for patients develop-
ing type-1 HRS while awaiting liver transplantation is an attrac-
tive approach to improve the outcome after transplantation and
may reduce the requirements of renal replacement therapy and
the need for combined liver–kidney transplantation [9,10]. The
main problems of terlipressin are its relatively high cost, particu-
larly for some areas of the world (yet its cost has decreased dra-
matically in some countries because of the recent introduction
of generic terlipressin), and a signiﬁcant frequency of side effects,
mainly ischemic complications, due to its powerful vasoconstric-
tor action on several vascular beds, such as the splanchnic circu-
lation, skin and muscle, and heart. Nevertheless, side effects can
beminimized by starting therapywith low doses andmaintaining
a strict clinical surveillance of patients throughout the treatment.
The study by Boyer et al. [11] published in the current issue of
the Journal of Hepatology represents a signiﬁcant contribution to
the improvement of our knowledge on the management of type-
1 HRS. The study is a report of a post hoc analysis of 112 patientsJournal of Hepatology 20
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ison of terlipressin and albumin vs. placebo [8], and was aimed at
assessing predictive factors of response to therapy and correlating
changes in systemic hemodynamics with changes in renal func-
tion. The results have important clinical and pathophysiological
implications. From a clinical standpoint, this study demonstrates
that serum creatinine concentration before the treatment was the
only independent predictive factor in reversal of type-1 HRS by
terlipressin and albumin, patients with lower serum creatinine
levels being those with the highest likelihood of response to ther-
apy. Reversal of HRS was very unusual in patients with pretreat-
ment serum creatinine levels above 5 mg/dl. Serum creatinine
was also found to be an important predictive factor of response
to therapy of type-1 HRS in previous studies including a lower
number of patients [7]. These ﬁndings deliver an important clini-
cal concept that is, early treatment of type-1 HRS with terlipressin
and albumin enhances the chances of response. Translated into
clinical practice, this means that the diagnosis of type-1 HRS
should be performed within a short time frame, ideally 24–48 h,
following the currently accepted guidelines [12], and the treat-
ment with terlipressin and albumin should be started as soon as
the diagnosis is made. From a pathophysiological perspective,
the study by Boyer et al. [11] shows that patients who responded
to terlipressin had an increase in arterial pressure which was fol-
lowed by an improvement in renal function, whereas in non-
responders to terlirpressin, arterial pressure did not change, and
renal function did not improve or continue to decline. These ﬁnd-
ings are in keeping with those from previous studies including a
lower number of patients [13,14]. Interestingly, a recent investi-
gation showed that patients in whom mean arterial pressure
increased by more than 5 mm Hg at day 3 of the treatment had
a greater probability of response than those in whom arterial
pressure increased less than 5 mm Hg (73% vs. 36%, respectively)
[13]. Unfortunately, in the study by Boyer et al. [11] the activity of
vasoconstrictor systems, particularly the renin-angiotensin-aldo-
sterone system and the sympathetic nervous system, which are
important players in the maintenance of circulatory function in
cirrhosis, was not assessed. Previous studies have shown that
response to terlipressin and albumin is associated not only with
an increase in arterial pressure but also with marked suppression
of the activity of the renin-angiotensin system and sympathetic11 vol. 55 j 268–269
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nervous system [13]. This suppression of the activity of the vaso-
constrictor systems has also been demonstrated in patients with
type-1 HRS showing response to other vasoconstrictor drugs, such
as ornipressin, midodrine, and norepinephrine [15–17]. Con-
versely, no such suppression occurs in patients who do not
respond to vasoconstrictors. Taken together, these data unequiv-
ocally demonstrate that the severe renal dysfunction that occurs
in type-1 HRS is due to a marked impairment of circulatory func-
tion and that pharmacological improvement of the circulatory
function is able to reverse renal failure. The reason(s) why phar-
macological treatment is hardly effective in patients with very
advanced type-1 HRS (i.e. serum creatinine greater than 5 mg/
dl) is not known at present and deserves investigation. Possibili-
ties, among others, include an insufﬁcient vasoactive effect of
vasoconstrictor drugs, association of HRS with other causes of
renal failure, and progression of type-1 HRS from functional renal
failure to ischemic kidney damage.
Despite the recent advances in the management of HRS, a
number of important challenges remain ahead. First, the number
of patients not responding to pharmacological therapy (patients
in whom serum creatinine either does not decrease during the
treatment or decreases but not to a level below 1.5 mg/dl) is still
high [5]. New approaches should be investigated to increase the
percentage of responders. In this regard, it will be interesting to
evaluate the efﬁcacy of terlipressin given by continuous infusion
instead of i.v. bolus, as currently used in all published studies.
Studies in experimental animals and patients with septic shock
suggest that the beneﬁcial hemodynamic effects of terlipressin
are enhanced when used as continuous infusion compared to
intermittent administration [18,19]. A preliminary report of a
randomized study suggests that this might be the case also in
type-1 HRS, but deﬁnite results are needed [20]. Second, the com-
bination of pharmacological therapy with non-pharmacological
therapies should be investigated, particularly in severe cases that
have a low probability of response to pharmacological therapy
alone. In this regard, a recent study showed that the combination
of terlipressin and albumin and an extracorporeal liver support
system using fractionated plasma separation and adsorption
may improve survival in patients with type-1 HRS [21]. However,
since this observation was made with a subanalysis of a larger
study, speciﬁc studies assessing this strategy in a speciﬁc popula-
tion of patients with type-1 HRS should be performed. Third, the
efﬁcacy of pharmacological treatment of type-1 HRS associated
with infections is not known since studies reported so far have
excluded patients with active infections. Speciﬁc studies should
be performed in this patient population. Finally, most of the
information on the efﬁcacy of pharmacological treatment of
HRS refers to patients with type-1 HRS and little information
exists on the efﬁcacy and safety of the treatment in type-2 HRS.
Investigations should be performed to assess not only the efﬁcacy
of pharmacological treatment on renal function in these patients
but also in the long-term outcomes, particularly the occurrence of
type-1 HRS and survival.Financial support
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